Introduction
. There is no report, however, on its activity against HSV-1 so far. In the present study, we show that the highly selective and potent inhibitors of the vacuolar protonATPase, Conmy A and Conmy B, are also potent inhibitors of HSV-1 replication and block both the penetration of the virus into host cells and the egress of the progeny viruses. In this study, the antiviral activity and specificity of Conmy A were evaluated by several experimental systems.
Materials and Methods

Isolation of concanamycins
Streptomyces sp. strain FK51 was fermented in Q medium (2.0% glycerin, 1.0% molasses, 0.5% casein, 0.1% polypepton and 0.4% CaCO 3 , pH 7.2) at 27˚C for 5 days. The culture broth of this strain (16 l) was separated into mycelia and supernatant fractions by centrifugation (3000 rpm, 10 min). The mycelia fraction was extracted with acetone and the extract was concentrated in vacuo to give a brown solid (80.1 g). The methanol-soluble part of this extract (74.6 g) was loaded on a silica gel column (7.4×47.0 cm), which was eluted stepwise with CHCl 3 , then with 2%, 5%, 10% and 20% methanol in CHCl 3 , with methanol and finally with H 2 O. The eluates were separated into four fractions on the basis of their thin layer chromatography patterns: fraction 1 was eluted with CHCl 3 and 2% methanol in CHCl 3 ; fraction 2 with 5%; fraction 3 with 20-100%; and fraction 4 with H 2 O. The yields were 10.9 g, 11.4 g, 5.9 g and 9.4 g for fractions 1, 2, 3 and 4, respectively. Fraction 2, found to be antiherpetically active, was dissolved in a small volume of CHCl 3 , applied to a silica gel column (2.1×53.0 cm), and eluted with 5-10% methanol in CHCl 3 . Similar sub-fractions were pooled and concentrated in vacuo to give a brown viscous oil (4.76 g), which was applied to an activated charcoal column (2.3×7.5 cm) and eluted with methanol. The eluate was evaporated in vacuo to yield a colourless powder (3.59 g) that was further separated by preparative HPLC to afford concanamycins A (23 mg) and B (78 mg) as well as 21-O-methylconcanamycins A (166 mg) and B (95 mg). The HPLC was performed under the following conditions: column, Cosmosil 5C18-MS, nacalai tesque, 20×250 mm; mobile phase, CH 3 CN-H 2 O (2:1); flow rate, 5.0 ml/min; pump, Shimadzu LC-6A liquid chromatograph; detection, 245 nm.
Cell and virus
Vero cells were grown in Eagle's minimum essential medium (MEM) supplemented with 5% fetal bovine serum (FBS). HSV-1 (HF strain) was propagated on Vero cells. After three cycles of freeze-thawing and centrifugation (3000 rpm, 10 min), the supernatant was stored as an infectious preparation at -80˚C.
Cytotoxicity
For cell growth inhibition studies, Vero cells were cultured for 72 h at 37˚C in the presence of increasing concentrations of the tested compound. Viable cell yield was determined by the trypan blue exclusion test. Inhibition data were plotted as dose-response curves, from which the 50% cell growth inhibitory concentration (CC 50 ) was obtained.
Antiviral activity
Vero cell monolayers were infected with HSV-1 at 0.1 plaque-forming unit (pfu) per cell at room temperature. After 1 h of viral infection, the monolayers were washed three times with phosphate-buffered saline (PBS) and incubated in maintenance medium (MEM plus 2% FBS) at 37˚C. The compound was added immediately after the virus infection (0 h). Virus yields were determined by plaque assay at the 1-day incubation point. Antiviral activity was expressed as the 50% virus replication inhibitory concentration (IC 50 ), which was the lowest compound concentration that reduced plaque number by 50% in the treated cultures compared with untreated ones. In time-ofaddition experiments, cells were infected with the virus at 10 pfu per cell, and the compounds added at the indicated time.
Inhibition of virus adsorption
The effect of concanamycins on the binding step of HSV-1 was studied by means of an infectious center assay (Andries et al., 1992) . Briefly, a suspension of Vero cells was resuspended in MEM to a final density of 4×10 6 cells/ml, and cooled at 4˚C for at least 2 h. HSV-1 (1 pfu/cell) and different concentrations of the drug were cooled to 4˚C and then added to the Vero cell suspension. The mixtures were incubated for 1 h at 4˚C to prevent the virus from penetrating into the cells. After the adsorption period, unbound virus and free drug were removed by washing three times with ice-cold PBS. The cell pellets were diluted serially with cold PBS and added to Vero cell monolayers, which were overlaid with maintenance medium containing 0.5% methylcellulose to be plaque-assayed.
Assay of rate of virus penetration
Virus penetration into host cells was measured by the method reported by Huang & Wagner (1964) and modified by Highlander et al. (1987) . Vero cell monolayers were cooled at 4˚C for 2 h and incubated with HSV-1 (~100 pfu/well) at 4˚C. After 1 h of adsorption, the inoculum was removed by washing three times with cold PBS, and fresh maintenance medium containing different concentrations of drug was added. Virus penetration was permitted by shifting the temperature to 37˚C. At the indicated time, unpenetrated viruses were inactivated by treatment with citrate buffer (pH 3.0) for 1 min. The monolayers were overlaid with 0.5% methylcellulose and incubated for 1 day to be plaque-assayed.
Assay of virus release into the medium
Vero cell monolayers were infected with HSV-1 at 0.1 or 10 pfu per cell. After 1 h of adsorption, they were washed three times with PBS and incubated at 37˚C in maintenance medium. After 30 min incubation, the cells were treated with citrate buffer (pH 3.0) to inactivate the inoculated virions that remained unpenetrated, and cultured in fresh maintenance medium containing different concentrations of drug. At 24 h post-infection (p.i.), the medium was harvested into tubes. The infected cell monolayers were washed five times with cold PBS and subjected to three cycles of freeze-thawing. Virus yields in the medium and cells were separately determined by plaque assay.
SDS-PAGE analysis of radio-labelled proteins
For the analysis of the effect of conanamycin A on host cell protein synthesis, Vero cells in 24-well plates were radio-labelled with 1 µCi of Tran 35 S-label (43.47 TBq/mmol; ICN Biomedicals, Costa Mesa, Calif., USA) per well for 4 h in methionine-free MEM (Flow Laboratories, Irvine, UK) containing the compound. In the infection experiments, Vero cells were infected with HSV-1 at 10 pfu per cell, washed with PBS and replenished with methionine-free MEM. For labelling of α (immediately early) proteins of HSV-1, Vero cells were incubated in the presence of 50 µg/ml of cycloheximide from 2 h before infection (-2 h) to 2 h p.i. These cells were infected with virus for 1 h (0 h), and then radiolabelled for 1 h during 2-3 h p.i. with Tran 35 S-label in the presence of 10 µg/ml of actinomycin D. The drug was added during 0-2 h p.i., during 2-3 h p.i., or during 0-3 h p.i. For labelling of both α and β (early) proteins, Vero cells were treated with 300 µg/ml of phosphonoacetic acid (PAA) from 2 h before infection to 4 h p.i., and incubated during 0-4 h p.i. with the medium supplemented with drug and Tran 35 S-label. For labelling γ (late) proteins, HSV-1-infected cells were incubated in the presence of drug for 8 h, and radio-labelled with Tran 35 S-label from 4-8 h p.i. Radio-labelled cells were harvested and extracted with cell lysis buffer (0.05 M Tris-HCl, pH 7.0, 0.15M NaCl, 1% SDS, 1% Triton X-100). For labelling of progeny viruses released to medium, Vero cells were infected with HSV-1 at 0.1 pfu per cell and incubated in the presence of drug and Tran 35 S-label. At 24 h p.i., the medium was collected and centrifuged at 3000 rpm for 15 min. The supernatant was centrifuged at 24000 rpm for 1 h to obtain virus pellets, which were extracted with cell lysis buffer. In another experiment, Vero cells were infected with HSV-1 at 10 pfu per cell and radio-labelled with 2 µCi of 14 C-glucosamine (278 mCi/mmol, Moravek Biochemicals, Brea, Calif., USA) from 3 to 10 h p.i., in the presence of 1 ng/ml of Conmy A or Conmy B. An aliquot of the cell lysates was treated with rabbit anti-HSV-1 serum (Hayashi et al., 1992) and Protein A Sepharose 4B Fast Flow (Pharmacia Biotech AB, Uppsala, Sweden) overnight at 4˚C with rocking. The immuno-precipitates and cell lysates were analysed by SDS-PAGE (8% polyacrylase). After electrophoresis, the gels were soaked in 1 M sodium salicylate for 30 min, dried, and exposed to X-ray films (Sambrook et al., 1989) .
Western blot analysis of viral glycoproteins
Vero cells were infected with HSV-1 at 1 pfu per cell. After 24 h of incubation in the absence or presence of Conmy A (0.5 or 1 ng/ml), whole cell extracts were prepared in cell lysis buffer. The cell extracts were subjected to 7.5 or 12% SDS-PAGE. Resulting gels were blotted on nitrocellulose filters in 25 mM Tris, 192 mM glycine and 20% methanol. Blotted proteins were immuno-reacted with rabbit antibodies prepared against synthesized 15-mer oligopeptides of HSV-1 gC (amino acids 113-127) and gD (amino acids 329-343) coupled to thyroglobulin. Bands were revealed using a peroxidase-conjugated goat anti-rabbit IgG (H+L) (CAPPEL, West Chester, Pa., USA) and 4-chloro-1-naphthol or luminol reagent (Western Blotting Luminol Reagent, Santa Cruz Biotechnology, Santa Cruz, Calif., USA).
Examination of plaque morphology
Vero cell monolayers were infected with HSV-1 at a very low titre of 0.001 pfu per cell and incubated for 24 h in the absence or presence of 1 ng/ml of Conmy A or Conmy B.
Plaque-forming cells were fixed and stained with Giemsa's solution.
Serial passage of virus in Conmy A
In order to select Conmy A-resistant mutants, HSV-1 was propagated by serial passage in the presence of the compound. Confluent Vero cell monolayers were infected with HSV-1 at 0.1 pfu per cell, and incubated at 37˚C in the presence of 1 ng/ml of Conmy A. At maximal cytopathic effect, cultures were harvested, and the titre was determined. Three serial passages were made at 0.1 pfu per cell in 5 ng/ml of Conmy A, three serial passages in 20 ng/ml of Conmy A, and then three serial passages in 100 ng/ml of Conmy A. The progeny viruses were plaque-purified and their sensitivities (IC 50 ) were determined by plaque reduction assays, with increasing concentrations of Conmy A in the overlying medium containing 0.5% methylcellulose.
Results
Effects of concanamycins on cell proliferation and virus replication
Uninfected Vero cells were cultured for 72 h in a medium containing 0.1-100 µg/ml of Conmy A or Conmy B. The CC 50 s of Conmy A and Conmy B were 10.5 and 12.3 µg/ml, respectively ( 
Effects of concanamycins on various stages of virus replication
To find a clue to the understanding of the mechanism of antiviral action of the concanamycins, the drug-sensitive phases were determined by time-of-addition experiments.
In these experiments, Vero cells were infected with HSV-1 at a high titre of 10 pfu per cell. As shown in Table 2 , Conmy A exerted potent inhibition against virus replication in all the treatments with lower efficacy in the cultures treated with drug only during infection for 1 h. Conmy B showed similar tendency to Conmy A, but the intensity of its antiviral activity was less than that of Conmy A. These results indicate that the concanamycins might interfere with very early stages to late stages of HSV-1 replication.
Effects of concanamycins on virus binding and penetration
In order to evaluate the special stages of virus replication which could be prevented by concanamycins, their inhibitory effects on virus adsorption were studied. Both Conmy A and Conmy B did not interfere with the attachment to host cell membranes at concentrations of 0.1-10 ng/ml (data not shown). The kinetics of penetration was determined by inactivating the bound but unpenetrated viruses with a low-pH citric acid buffer at various times after temperature shift from 4 to 37˚C (Table 3) . Penetration of HSV-1 into the cells was almost completely inhibited in the presence of 2 or 10 ng/ml of Conmy A and Conmy B, respectively.
Effects of concanamycins on protein synthesis
The concanamycins did not inhibit protein synthesis of uninfected Vero cells at concentrations up to 1 ng/ml ( Figure  1, a) . When Vero cells were infected with HSV-1 and Conmy A was added at 0-4 h p.i. in the presence of PAA, an inhibitor of γ protein synthesis (Honess & Watson, 1977) , the compound inhibited dose-dependently the bulk of virusspecific protein synthesis (Figure 1, b) . During this period of virus replication, both α and β proteins of HSV-1 are mainly synthesized. So, in order to make clear the effect of Conmy A on HSV-1 α proteins, the infected cells were Table 3 . Inhibitory effects of concanamycins on virus penetration process p.i., post-infection. *The plaque number per well at 3 h postinfection in no-drug control cultures was taken as 100%, which was equivalent to 111 pfu/well.
treated with cyclohexide and then actinomycin D, since α proteins could be accumulated in the cells by treating with actinomycin D following the infection of cells in the presence of cycloheximide (Hayashi et al., 1992) . The expression of α proteins was not markedly suppressed when infected cells were treated with Conmy A during transcription of viral DNA to mRNA (-2 to 2 h p.i.), translation (2-3 h p.i.) or both transcription and translation (-2 to 3 h p.i.)(data not shown). Thus, the changes in protein synthesis by Conmy A during 0-4 h p.i. could be attributed to the inhibition of HSV-1 β proteins. In infected cells treated with Conmy A during the period of 4-8 h p.i., no marked reduction in the level of viral protein synthesis was detected (Figure 1, c) . However, the mobility of the protein(s) with a molecular weight of about 120 kDa was faster in the cells treated with 1 ng/ml of Conmy A than that of untreated cells. To confirm whether the affected protein(s) was glycoprotein(s) or not, infected Vero cells were radio-labelled with 
Effects of concanamycins on the release of progeny virions
To confirm that concanamycins inhibit the virus release from infected cells, both cell-associated and extracellular viruses were separately titred by plaque assay. HSV-infected cells at 0.1 pfu/cell were treated with the compounds for 24 h, as described under Materials and Methods. Under this condition no reduction in the yield of cell-associated virus was observed in the presence of the concanamycins at 0.2 ng/ml or less, while 30-35% reduction was found in released viruses at these concentrations (Figure 3) . At 1 ng/ml or higher concentrations, the compounds produced the inhibitory effects on the yield of cell-associated viruses accompanied by stronger repression of virus release. Metabolic labelling of virus-specific proteins with [
35 S] amino acids was performed in the presence of increasing concentrations of Conmy A or Conmy B (Figure 4) . The labelling levels in released progeny virions were reduced by these drugs. In progeny viruses, it was again clearly demonstrated that the proteins with molecular weights of about 120 kDa electrophoresed a little faster after treatment with Conmy A and Conmy B, compared with those of the untreated control. Similar results were obtained when Vero cells were infected with HSV-1 at a high MOI of 10 pfu/cell.
Western blot analysis of virus-specific glycoproteins
In order to confirm the effects of Conmy A on the synthesis of HSV-1 glycoproteins, two virus-specific glycoproteins, gC and gD, were detected by immunoblotting using each antibody, after the treatment of infected cells with Conmy A for 24 h ( Figure 5 ). The cell extracts yielded two species of gC, which correspond to the precursor (pgC) and mature (gC) forms of gC (Marsden, 1987) . While no marked change in pgC profile was induced by Conmy A, the migrating rate of gC was clearly modified by drug treatment at the concentrations of 0.5 and 1 ng/ml, indicating a decrease in the molecular weight of the glycoprotein. The change in molecular weight of gC was estimated as 10-15 kDa. The glycoprotein gD was also detected as its precursor and in mature forms. In the cells treated with Conmy A, the molecular weight of gD decreased by up to 
Effect of concanamycins on the plaque morphology
HF strain of HSV-1, used in the present study, forms syncytial plaques on permissive cell lines such as Vero cells. When this strain was propagated in the presence of either Conmy A or B, the plaques with rounded cells were formed and no syncytium-forming plaque was observed (Figure 6 ). The plaque size of drug-treated virus determined at 24 h post-infection was much smaller than that of untreated one.
Effect of serial treatments with concanamycin A on the drug sensitivity and plaque morphology of progeny After ten passages of HSV-1 HF strain in increasing concentrations of Conmy A, resultant viruses, which did not show the normal plaque morphology of syncytium but showed rounding of cells, were selected. Two plaque-purified progeny viruses were determined for their sensitivities to the compound. Their IC 50 s were ranged in 0.058-0.067 ng/ml, compared to 0.071 ng/ml for the parent virus.
To determine whether the wild-type plaque morpholo- gy returned when these viruses were propagated in drugfree medium, these two progenies were inoculated into Vero cell monolayers. After one passage, both the viruses showed exclusively normal plaque morphology of syncytium.
Discussion
In this study, we evaluated the anti-herpetic activities of concanamycins A and B. Both Conmy A and Conmy B were proved to have high activities against HSV-1. Previous reports showed that Conmy A did not prevent the attachment of influenza A virus to cells (Guinea & Carrasco, 1994) . This early step of replication was, likewise, not inhibited by Conmy A in HSV-infected cells. On the other hand, Conmy A and Conmy B showed inhibitory effects on HSV-1 entry into cells, which takes place immediately after binding to the cells. Because the concanamycins are potent inhibitors of the vacuolar protonATPase, and thus prevent acidification of endosomes, these drugs should block the entry of some viruses such as influenza A virus, which requires a low pH during penetration into cells (Guinea & Carrasco, 1994) . In HSV-1 replication, where the entry into host cells occurs through a pHindependent fusion event (Wittels & Spear, 1990; Spear, 1993) , it was unlikely that neutralization by the concanamycins attributed to the inhibition of fusion between the virus envelope and cellular membranes. Therefore, as Guinea and Carrasco (1994) indicated, not acidic conditions but a pH gradient might be necessary to induce HSV-1 entry into host cells. Sindbis virus is another virus which is inhibited at the step of primary infection by Conmy A (Glomb-Reimund & Kielian, 1998) , in spite of the fact that this virus has been proposed to enter into cells by a mechanism independent of a low pH (Brown & Edwards, 1992) . In influenza virus-infected cells, addition of Conmy A during infection inhibited infectivity but addition immediately after infection did not (Guinea & Carrasco, 1994) . Similar results have been reported in Sindbis virus-infected cells (Glomb-Reimund & Kielian, 1998) . In contrast, in our time-of-addition experiments, where Conmy A was added at various times after HSV-1 infection, the results suggested that not only early events but also later intracellular events in virus infection might be the targets of the compound. Conmy A showed moderate inhibition of HSV-1 β proteins but not α proteins, although the mechanism of action remains unclear. Further search for the steps of virus replication at which this agent could affect to result in the restriction of virus progeny production revealed that synthesis of HSV-specific glycoproteins with reduced molecular weights and suppression of the egress of progeny viruses took place by Conmy A. As vacuolar proton-ATPase is localized among various intracellular organelles participating in trafficking of glycoproteins such as endosomes, lysosomes and the trans Golgi network (Forgae, 1989) , perturbation of the acidic pH should result in blocking of glycoprotein trafficking (Mellman et al., 1986) . Thus, Conmy A, a specific vacuolar proton-ATPase inhibitor, could be expected to play a role in inhibiting intracellular translocation of glycoproteins. Indeed, Conmy A blocked excretion of the glycoprotein of vesicular stomatitis virus into the medium, and the glycoprotein synthesized in the presence of Conmy A was shown as immature (Muroi et al., 1993) . These results indicate that in the presence of Conmy A, processing of N-glycosidic oligosaccharide remains incomplete and intracellular trafficking is arrested before reaching the latest of the trans-Golgi compartments. HSV-specific glycoproteins C and D detected after Conmy A treatment in the present study would be presumed as the immature forms with high-mannose glycans. The inhibition of the maturation of virus glycoproteins by Conmy A would explain the decrease in released viruses, because conversion of high-mannose glycans into complex-type glycans in Golgi apparatus appears to be required for the egress of the virion from the HSV-infected cells (Campadelli-Fiume et al., 1982; Johnson & Spear, 1982; Selafini-Cessi et al., 1983; Kousoulas et al., 1984) . The plaque morphology of rounded cells was observed in concanamycin-treated cell cultures. This could be also explained by the immature synthesis of virus-specific glycoproteins, which should affect the cell-to-cell spread of virus, a phenomenon by which plaque morphology of infected cells can be determined (Roop et al., 1993; Dingwell et al., 1994) . Smaller size of plaques observed in drug-treated cells might reflect the reduced production of progeny viruses. In the present study, Conmy B also proved to exert a similar effect to Conmy A on the processing of the viral envelope glycoproteins, but to a lesser degree.
To determine whether a chemical substance would be a specific antiviral agent, it is important to obtain and characterize the resistant mutants. In the present study, however, it was shown that serial passages of virus under the selective pressure of Conmy A never rendered the progeny drug-resistant. In conclusion, it was suggested that the concanamycins might act primarily by limiting the maturation of HSV-specific glycoproteins, as a result of the inhibition of vacuolar proton-ATPase.
